DK1810676T3 - Levetiracetam formuleringer og fremgangsmåder til deres fremstilling - Google Patents

Levetiracetam formuleringer og fremgangsmåder til deres fremstilling

Info

Publication number
DK1810676T3
DK1810676T3 DK06251210T DK06251210T DK1810676T3 DK 1810676 T3 DK1810676 T3 DK 1810676T3 DK 06251210 T DK06251210 T DK 06251210T DK 06251210 T DK06251210 T DK 06251210T DK 1810676 T3 DK1810676 T3 DK 1810676T3
Authority
DK
Denmark
Prior art keywords
methods
preparation
levetiracetam
compositions
formulations
Prior art date
Application number
DK06251210T
Other languages
English (en)
Inventor
Julia Hrakovsky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1810676(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1810676T3 publication Critical patent/DK1810676T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK06251210T 2006-01-24 2006-03-07 Levetiracetam formuleringer og fremgangsmåder til deres fremstilling DK1810676T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76210306P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
DK1810676T3 true DK1810676T3 (da) 2009-02-09

Family

ID=36337638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06251210T DK1810676T3 (da) 2006-01-24 2006-03-07 Levetiracetam formuleringer og fremgangsmåder til deres fremstilling

Country Status (13)

Country Link
US (1) US20070172521A1 (da)
EP (1) EP1810676B1 (da)
JP (1) JP2009524658A (da)
CN (1) CN101360493A (da)
AT (1) ATE413875T1 (da)
CA (1) CA2637925A1 (da)
DE (1) DE602006003617D1 (da)
DK (1) DK1810676T3 (da)
ES (1) ES2317452T3 (da)
IL (1) IL193024A0 (da)
PL (1) PL1810676T3 (da)
PT (1) PT1810676E (da)
WO (1) WO2007086891A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049642A1 (en) * 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
WO2009069089A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN101693017B (zh) * 2009-10-28 2012-06-06 北京赛科药业有限责任公司 左乙拉西坦的药物组合物及其制备方法
EP2563340A2 (en) 2010-04-26 2013-03-06 Mahmut Bilgic Water soluble pharmaceutical composition
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
CN102379857B (zh) * 2011-05-30 2013-10-09 深圳信立泰药业股份有限公司 一种左乙拉西坦缓释药物组合物及其制备方法
CN102764254B (zh) * 2012-05-16 2016-09-07 深圳信立泰药业股份有限公司 一种左乙拉西坦药物组合物及其制备方法
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7575217B2 (ja) * 2019-08-09 2024-10-29 日本ジェネリック株式会社 レベチラセタムを含む錠剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514389A (en) * 1981-05-06 1985-04-30 Kyowa Chemical Industry Co. Ltd. Gastric antacid and method for controlling pH of gastric juice
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
CA2392879C (en) * 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
CN1205938C (zh) * 2002-10-08 2005-06-15 深圳海王药业有限公司 具有改善哺乳动物微循环作用的产品
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
WO2005023763A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
PL1909764T3 (pl) 2005-07-26 2015-03-31 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania

Also Published As

Publication number Publication date
ES2317452T3 (es) 2009-04-16
JP2009524658A (ja) 2009-07-02
EP1810676B1 (en) 2008-11-12
CA2637925A1 (en) 2007-08-02
ATE413875T1 (de) 2008-11-15
EP1810676A1 (en) 2007-07-25
US20070172521A1 (en) 2007-07-26
CN101360493A (zh) 2009-02-04
WO2007086891A1 (en) 2007-08-02
IL193024A0 (en) 2009-02-11
DE602006003617D1 (de) 2008-12-24
PL1810676T3 (pl) 2009-04-30
PT1810676E (pt) 2009-01-02

Similar Documents

Publication Publication Date Title
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
NO20092611L (no) Krystallinsk faststoff Rasagilin base
EP2535058A3 (en) Stabilization of vaccines by lyophilization
DK1909764T3 (da) Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
WO2008049116A3 (en) Substituted indoles
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
DK2460820T3 (da) PCV2-immunogene sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger
DK3320919T3 (da) Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille sådanne sammensætninger
NO20084850L (no) MGLUR5 modulatorer I
WO2007106746A3 (en) Formulations for ecallantide
IL192108A (en) Triazulophyridines, pharmaceutical preparations and combinations containing them, process for their preparation and use as modulators of tyrosine kinase
NO20081160L (no) Benzimidazoltiofen forbindelser
GEP20094784B (en) Sustained release pharmaceutical formulations
NO20084852L (no) MGLUR5 modulatorer V
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1862158T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
TW200738649A (en) Calcilytic compounds
DK2084183T3 (da) Pegyleret PTH som PTH-receptormodulatorer og anvendelser deraf
ATE429906T1 (de) Trockene aripiprazolformulierungen
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
ATE552832T1 (de) Antidepressivum-propharmaka